

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 1E




Fig. 1F




Fig. 2

BEST AVAILABLE COPY




Fig. 3A




Fig. 3B




Fig. 3C




Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4D




Fig. 4E




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6D




Fig. 6E




Fig. 7




Fig. 8A






Fig. 8C


Untreated

Anti-p65

Hoechst



NBD-treated



BEST AVAILABLE COPY

Fig. 8B




Fig. 9





Fig. 10A

BEST AVAILABLE COPY



BEST AVAILABLE COPY

Fig. 10B




Fig. 11A

BEST AVAILABLE COPY

EMSA






Fig. 11B



BEST AVAILABLE COPY

Fig. 12A



BEST AVAILABLE COPY

Fig. 12B




Fig. 12C

BEST AVAILABLE COPY




Fig. 13A

BEST AVAILABLE COPY

STAT3




Fig. 13B

BEST AVAILABLE COPY




Fig. 14A




Fig. 14B




Fig. 14C





Fig. 14D


NF- κ B (p65)

Patient #20

None



Curcumin



Dexamethason





Fig. 15A


STAT3

Patient #20


None



Curcumin



Dexamethason



BEST AVAILABLE COPY

Fig. 15B




Fig. 16A




Fig. 16B